RESUMEN
The aim of our study was to explore the effects of regular aerobic exercise on anthropometric, biochemical and hormonal parameters and mRNA expression of selected factors involved in metabolic regulations in subcutaneous adipose tissue of patients with obesity. Fifteen obese women with arterial hypertension underwent a three-month exercise program consisting of 30 min of aerobic exercise 3 times a week. Fifteen healthy lean women with no intervention served as a control group. Obese group underwent anthropometric measurements, blood sampling, subcutaneous adipose tissue (SCAT) biopsy and 24-h blood pressure monitoring at baseline and after three months of exercise, while control group was examined only once. At baseline, obese group had increased SCAT expression of proinflammatory cytokines and adipokines relative to control group. Three months of regular exercise improved anthropometric parameters, decreased CRP, blood glucose and HOMA-IR, while having no significant effect on lipid profile and blood pressure. Gene expressions in SCAT were not affected by physical activity with the exception of increased aquaporin-3 mRNA expression. We conclude that three months of regular exercise decrease systemic subclinical inflammation with only minor influence on the blood pressure and the endocrine function of subcutaneous fat.
Asunto(s)
Presión Arterial , Terapia por Ejercicio , Hipertensión/fisiopatología , Mediadores de Inflamación/sangre , Inflamación/terapia , Obesidad/terapia , Grasa Subcutánea/metabolismo , Adipoquinas/sangre , Adipoquinas/genética , Biomarcadores/sangre , Citocinas/sangre , Citocinas/genética , Femenino , Humanos , Hipertensión/diagnóstico , Inflamación/sangre , Inflamación/diagnóstico , Inflamación/genética , Resistencia a la Insulina , Persona de Mediana Edad , Obesidad/sangre , Obesidad/diagnóstico , Obesidad/fisiopatología , ARN Mensajero/sangre , Factores de Tiempo , Resultado del TratamientoRESUMEN
Omentin is a novel adipokine with insulin-sensitizing effects expressed predominantly in visceral fat. We investigated serum omentin levels and its mRNA expression in subcutaneous adipose tissue (SCAT) of 11 women with type 2 diabetes mellitus (T2DM), 37 obese non-diabetic women (OB) and 26 healthy lean women (C) before and after various weight loss interventions: 2-week very-low-calorie diet (VLCD), 3-month regular exercise and laparoscopic sleeve gastrectomy (LSG). At baseline, both T2DM and OB groups had decreased serum omentin concentrations compared with C group while omentin mRNA expression in SCAT did not significantly differ among the groups. Neither VLCD nor exercise significantly affected serum omentin concentrations and its mRNA expression in SCAT of OB or T2DM group. LSG significantly increased serum omentin levels in OB group. In contrast, omentin mRNA expression in SCAT was significantly reduced after LSG. Baseline fasting serum omentin levels in a combined group of the studied subjects (C, OB, T2DM) negatively correlated with BMI, CRP, insulin, LDL-cholesterol, triglycerides and leptin and were positively related to HDL-cholesterol. Reduced circulating omentin levels could play a role in the etiopathogenesis of obesity and T2DM. The increase in circulating omentin levels and the decrease in omentin mRNA expression in SCAT of obese women after LSG might contribute to surgery-induced metabolic improvements and sustained reduction of body weight.
Asunto(s)
Restricción Calórica/métodos , Citocinas/sangre , Diabetes Mellitus Tipo 2/sangre , Lectinas/sangre , Actividad Motora/fisiología , Obesidad Mórbida/sangre , Grasa Subcutánea/metabolismo , Adulto , Citocinas/biosíntesis , Diabetes Mellitus Tipo 2/epidemiología , Diabetes Mellitus Tipo 2/terapia , Femenino , Estudios de Seguimiento , Proteínas Ligadas a GPI/biosíntesis , Proteínas Ligadas a GPI/sangre , Gastrectomía/métodos , Regulación de la Expresión Génica , Humanos , Laparoscopía/métodos , Lectinas/biosíntesis , Persona de Mediana Edad , Obesidad Mórbida/epidemiología , Obesidad Mórbida/terapia , ARN Mensajero/biosíntesisRESUMEN
Adipocyte fatty acid binding protein (A-FABP) is a novel adipokine involved in the regulation of lipid and glucose metabolism and inflammation. To evaluate its potential role in the development of postoperative hyperglycemia and insulin resistance we assessed A-FABP serum concentrations and mRNA expression in skeletal and myocardial muscle, subcutaneous and epicardial adipose tissue and peripheral monocytes in 11 diabetic and 20 age- and sex-matched non-diabetic patients undergoing elective cardiac surgery. Baseline serum A-FABP did not differ between the groups (31.1+/-5.1 vs. 25.9+/-4.6 ng/ml, p=0.175). Cardiac surgery markedly increased serum A-FABP in both groups with a rapid peak at the end of surgery followed by a gradual decrease to baseline values during the next 48 h with no significant difference between the groups at any timepoint. These trends were analogous to postoperative excursions of plasma glucose, insulin and selected proinflammatory markers. Cardiac surgery increased A-FABP mRNA expression in peripheral monocytes, while no effect was observed in adipose tissue or muscle. Our data suggest that circulating A-FABP might be involved in the development of acute perioperative stress response, insulin resistance and hyperglycemia of critically ill irrespectively of the presence of diabetes mellitus.
Asunto(s)
Tejido Adiposo/metabolismo , Procedimientos Quirúrgicos Cardíacos , Proteínas de Unión a Ácidos Grasos/biosíntesis , Monocitos/metabolismo , ARN Mensajero/biosíntesis , Anciano , Biomarcadores/sangre , Procedimientos Quirúrgicos Cardíacos/efectos adversos , Regulación de la Expresión Génica , Humanos , Masculino , Persona de Mediana EdadRESUMEN
Low-grade inflammation links obesity, insulin resistance, and cardiovascular diseases. We investigated the effects of laparoscopic sleeve gastrectomy (LSG) on expression profile of genes involved in inflammatory pathways in subcutaneous adipose tissue (SCAT) and peripheral monocytes (PM). At baseline, obese group had significantly increased mRNA expression of proinflammatory chemokines (CCL-3, -17, -22), chemokine receptor CCR1 and cytokines (IL-10, IL-18) in SCAT and chemokine and other proinflammatory receptors (CCR-1, -2, -3, TLR-2, -4) in PM relative to control group. LSG decreased body weight, improved metabolic profile and reduced mRNA expression of up-regulated chemokine receptors, chemokines and cytokines in SCAT. In contrast, expression profiles in PM were largely unaffected by LSG. We conclude that LSG improved proinflammatory profile in subcutaneous fat but not in peripheral monocytes. The sustained proinflammatory and chemotactic profile in PM even 2 years after LSG may contribute to partial persistence of metabolic complications in obese patients after metabolic surgery.
Asunto(s)
Gastrectomía/métodos , Expresión Génica , Monocitos/metabolismo , Obesidad/cirugía , ARN Mensajero/genética , Grasa Subcutánea/metabolismo , Adulto , Quimiocinas CC/genética , Quimiocinas CC/metabolismo , Femenino , Perfilación de la Expresión Génica , Humanos , Inflamación/genética , Inflamación/metabolismo , Inflamación/patología , Inflamación/cirugía , Interleucina-10/genética , Interleucina-10/metabolismo , Interleucina-18/genética , Interleucina-18/metabolismo , Laparoscopía , Persona de Mediana Edad , Monocitos/patología , Obesidad/genética , Obesidad/metabolismo , Obesidad/patología , Especificidad de Órganos , ARN Mensajero/metabolismo , Receptores CCR/genética , Receptores CCR/metabolismo , Grasa Subcutánea/patología , Receptor Toll-Like 2/genética , Receptor Toll-Like 2/metabolismo , Receptor Toll-Like 4/genética , Receptor Toll-Like 4/metabolismo , Pérdida de PesoRESUMEN
Appropriate differentiation capacity of adipose tissue significantly affects its ability to store lipids and to protect nonadipose tissues against lipid spillover and development of insulin resistance. Preadipocyte factor-1 (Pref-1) is an important negative regulator of preadipocyte differentiation. The aim of our study was to explore the changes in circulating Pref-1 concentrations in female subjects with obesity (OB) (n=19), females with obesity and type 2 diabetes mellitus (T2DM) (n=22), and sex- and age-matched healthy control subjects (C) (n=22), and to study its modulation by very low calorie diet (VLCD), acute hyperinsulinemia during isoglycemic-hyperinsulinemic clamp, and 3 months' treatment with PPAR-α agonist fenofibrate. At baseline, serum Pref-1 concentrations were significantly higher in patients with T2DM compared to control group, while only nonsignificant trend towards higher levels was observed in OB group. 3 weeks of VLCD decreased Pref-1 levels in both OB and T2DM group, whereas 3 months of fenofibrate treatment had no significant effect. Hyperinsulinemia during the clamp significantly suppressed Pref-1 levels in both C and T2DM subjects and this suppression was unaffected by fenofibrate treatment. In a combined population of all groups, circulating Pref-1 levels correlated positively with insulin, leptin and glucose levels and HOMA (homeostasis model assessment) index. We conclude that elevated Pref-1 concentrations in T2DM subjects may contribute to impaired adipose tissue differentiation capacity associated with insulin resistance in obese patients with T2DM. The decrease of Pref-1 levels after VLCD may be involved in the improvement of metabolic status and the amelioration of insulin resistance in T2DM patients.
Asunto(s)
Restricción Calórica , Diabetes Mellitus Tipo 2/sangre , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Fenofibrato/uso terapéutico , Hiperinsulinismo/sangre , Péptidos y Proteínas de Señalización Intercelular/sangre , Proteínas de la Membrana/sangre , Obesidad/sangre , Obesidad/dietoterapia , Antropometría , Peso Corporal , Proteínas de Unión al Calcio , Diabetes Mellitus Tipo 2/complicaciones , Femenino , Técnica de Clampeo de la Glucosa , Humanos , Hiperinsulinismo/tratamiento farmacológico , Persona de Mediana Edad , Obesidad/complicaciones , Obesidad/tratamiento farmacológico , PPAR alfa/agonistas , PPAR alfa/metabolismoRESUMEN
OBJECTIVE: Fibroblast growth factor (FGF)-19 and FGF-21 are novel metabolic regulators that improve insulin resistance and obesity in rodents. The aim of the study was to assess the effects of laparoscopic sleeve gastrectomy (LSG) on serum concentrations of FGF-19 and FGF-21 along with circulating bile acids and other relevant hormonal and biochemical parameters. DESIGN AND METHODS: Seventeen females with obesity undergoing LSG and 15 lean healthy females were included into the study. Anthropometric and biochemical parameters, serum concentrations of FGF-19 and -21, insulin, adiponectin, leptin, C-reactive protein, resistin, amylin (total), ghrelin (active), glucagon-like peptide 1 (GLP-1, active), glucose-dependent insulinotropic peptide (GIP, total), peptide YY (PYY, total), pancreatic polypeptide (PP), and bile acids, and mRNA expression of selected adipokines and inflammatory markers in bioptic samples of subcutaneous fat were assessed at baseline and 6, 12, and 24 months after LSG. RESULTS: LSG markedly decreased body weight, BMI, waist circumference, and insulin levels and improved systemic inflammation and lipid levels. FGF-19 concentrations increased and FGF-21 concentrations decreased after LSG along with increased adiponectin and decreased leptin, amylin, and ghrelin levels. GLP-1, GIP, PP, and circulating bile acids were not affected by LSG. PYY decreased significantly 24 months after surgery only. mRNA expression analysis in subcutaneous fat showed markedly reduced proinflammatory state. CONCLUSIONS: Our results indicate that increased FGF-19 and decreased ghrelin concentrations could have partially contributed to the improvement of systemic inflammation and some metabolic parameters after LSG, while changes of FGF-21 are rather secondary because of weight loss.
Asunto(s)
Factores de Crecimiento de Fibroblastos/sangre , Gastrectomía/métodos , Obesidad Mórbida/sangre , Obesidad Mórbida/cirugía , Adiponectina/sangre , Adulto , Ácidos y Sales Biliares/sangre , Índice de Masa Corporal , Proteína C-Reactiva/metabolismo , Femenino , Polipéptido Inhibidor Gástrico/sangre , Ghrelina/sangre , Péptido 1 Similar al Glucagón/sangre , Humanos , Insulina/sangre , Resistencia a la Insulina , Polipéptido Amiloide de los Islotes Pancreáticos/sangre , Leptina/sangre , Persona de Mediana Edad , Polipéptido Pancreático/sangre , Péptido YY/sangre , Estudios Prospectivos , ARN Mensajero/metabolismo , Resistina/sangre , Grasa Subcutánea/metabolismo , Circunferencia de la Cintura , Pérdida de PesoRESUMEN
Ghrelin and agonists of its receptor GHS-R1a are potential substances for the treatment of cachexia. In the present study, we investigated the acute and long term effects of the GHS R1a agonist JMV 1843 (H Aib-DTrp-D-gTrp-CHO) on food intake, body weight and metabolic parameters in lean C57BL/6 male mice. Additionally, we examined stability of JMV 1843 in mouse blood serum. A single subcutaneous injection of JMV 1843 (0.01-10 mg/kg) increased food intake in fed mice in a dose-dependent manner, up to 5-times relative to the saline-treated group (ED(50)=1.94 mg/kg at 250 min). JMV 1843 was stable in mouse serum in vitro for 24 h, but was mostly eliminated from mouse blood after 2 h in vivo. Ten days of treatment with JMV 1843 (subcutaneous administration, 10 or 20 mg/kg/day) significantly increased food intake, body weight and mRNA expression of the orexigenic neuropeptide Y and agouti-related peptide in the medial basal hypothalamus and decreased the expression of uncoupling protein 1 in brown adipose tissue. Our data suggest that JMV 1843 could have possible future uses in the treatment of cachexia.
Asunto(s)
Proteína Relacionada con Agouti/metabolismo , Estimulantes del Apetito/farmacología , Ingestión de Alimentos/efectos de los fármacos , Ghrelina/agonistas , Hipotálamo/efectos de los fármacos , Neuropéptido Y/metabolismo , Oligopéptidos/farmacología , Aumento de Peso/efectos de los fármacos , Tejido Adiposo Pardo/efectos de los fármacos , Tejido Adiposo Pardo/metabolismo , Proteína Relacionada con Agouti/genética , Animales , Estimulantes del Apetito/administración & dosificación , Estimulantes del Apetito/farmacocinética , Relación Dosis-Respuesta a Droga , Ghrelina/metabolismo , Hipotálamo/metabolismo , Indoles , Inyecciones Subcutáneas , Canales Iónicos/metabolismo , Masculino , Ratones , Ratones Endogámicos C57BL , Proteínas Mitocondriales/metabolismo , Neuropéptido Y/genética , Oligopéptidos/administración & dosificación , Oligopéptidos/farmacocinética , ARN Mensajero/metabolismo , Receptores de Ghrelina/agonistas , Receptores de Ghrelina/metabolismo , Transducción de Señal/efectos de los fármacos , Triptófano/análogos & derivados , Proteína Desacopladora 1 , Regulación hacia ArribaRESUMEN
OBJECTIVE: Recent studies linked circulating pigment epithelium-derived factor (PEDF) to obesity-associated insulin resistance, but the main source of circulating PEDF is unknown. We aimed to investigate liver and adipose tissue PEDF gene expression in association with obesity and insulin resistance. DESIGN, SUBJECTS AND METHODS: Three (two cross-sectional and one longitudinal) independent cohorts have been studied, for adipose tissue (n=80 and n=30) and liver gene expression (n=32 and n=14). Effects of high glucose and cytokines on HepG2 cell line were also investigated. PEDF gene expression and circulating PEDF were analyzed using real-time PCR and ELISA, respectively. RESULTS: In a first cohort of subjects, PEDF relative gene expression was higher in subcutaneous (SC) than in omental (OM) adipose tissue (P<0.0001) being also higher in mature adipocytes compared with stromo-vascular cells (P<0.0001). However, OM PEDF relative gene expression was decreased in morbidly obese subjects (P=0.01). Both OM PEDF and OM PEDF receptor (PEDFR) correlated positively with lipogenic and lipolytic genes, and with genes implicated in the lipid vacuole formation. Circulating PEDF levels were not associated with fat PEDF gene expression. In the second cohort, SC PEDF was decreased in subjects with type 2 diabetes and did not change significantly after weight loss. We next explored circulating PEDF in association with markers of liver-related insulin resistance injury (alanine aminotransferase, r=0.59, P=0.001). Interestingly, liver PEDF gene expression increased with obesity and insulin resistance in men, being significantly associated with fasting glucose and glycated hemoglobin in two independent cohorts. In fact, high glucose led to increased PEDF in HepG2 cells, while inflammatory stimuli present in the adipose tissue environment downregulated PEDF. CONCLUSION: Liver, but not adipose tissue, might be the source of increased circulating PEDF linked to insulin resistance.
Asunto(s)
Tejido Adiposo/metabolismo , Proteínas del Ojo/metabolismo , Resistencia a la Insulina , Hígado/metabolismo , Factores de Crecimiento Nervioso/metabolismo , Obesidad Mórbida/metabolismo , Serpinas/metabolismo , Adipocitos , Adulto , Índice de Masa Corporal , Diferenciación Celular , Células Cultivadas , Estudios Transversales , Ensayo de Inmunoadsorción Enzimática , Proteínas del Ojo/genética , Femenino , Células Hep G2 , Humanos , Resistencia a la Insulina/genética , Estudios Longitudinales , Masculino , Factores de Crecimiento Nervioso/genética , Obesidad Mórbida/epidemiología , Obesidad Mórbida/genética , Reacción en Cadena en Tiempo Real de la Polimerasa , Serpinas/genética , España/epidemiologíaRESUMEN
We explored serum concentrations and mRNA expression of insulin-like-growth factor-1 (IGF-1) axis components in subcutaneous adipose tissue (SCAT) and peripheral monocytes (PM) of 18 healthy females, 11 obese non-diabetic females (OB) and 13 obese women with type 2 diabetes (T2DM) examined at baseline and after very-low-calorie diet (VLCD). T2DM women had decreased expression of IGF-1, IGF-1 receptor (IGF-1R), IGFBP-2 (IGF binding protein-2) and IGFBP-3 in SCAT and increased expression of IGF-1R in PM compared to control group. IGF-1R and IGFBP-3 mRNA expression in SCAT of OB was comparable to control group. In T2DM women VLCD increased serum levels and SCAT expression of IGFBP-2 and PM expression of IGFBP-3. We conclude that decreased IGF-1, IGF-1R and IGFBP-3 expression in SCAT and increased IGF-1R expression in PM of T2DM subjects might contribute to changes of fat differentiation capacity and to regulation of subclinical inflammation by PM, respectively. Increased SCAT and circulating IGFBP-2 and IGFBP-3 in PM might participate in metabolic improvements after VLCD.
Asunto(s)
Restricción Calórica , Diabetes Mellitus Tipo 2/sangre , Diabetes Mellitus Tipo 2/complicaciones , Factor I del Crecimiento Similar a la Insulina/metabolismo , Obesidad/sangre , Obesidad/complicaciones , Transducción de Señal , Diabetes Mellitus Tipo 2/genética , Femenino , Regulación de la Expresión Génica , Hormonas/sangre , Humanos , Factor I del Crecimiento Similar a la Insulina/genética , Persona de Mediana Edad , Monocitos/metabolismo , Obesidad/genética , ARN Mensajero/genética , ARN Mensajero/metabolismo , Transducción de Señal/genética , Grasa Subcutánea/metabolismoRESUMEN
We studied the changes in serum fibroblast growth factor-21 (FGF-21) concentrations, its mRNA, and protein expression in skeletal muscle and adipose tissue of 15 patients undergoing cardiac surgery. Blood samples were obtained: prior to initiation of anesthesia, prior to the start of extracorporeal circulation, upon completion of the surgery, and 6, 24, 48, and 96 hours after the end of the surgery. Tissue sampling was performed at the start and end of surgery. The mean baseline serum FGF-21 concentration was 63.1 (43.03-113.95) pg/ml and it increased during surgery with peak 6 hours after its end [385.5 (274.55-761.65) pg/ml, p < 0.001], and returned to baseline value [41.4 (29.15-142.83) pg/ml] 96 hours after the end of the surgery. Serum glucose, insulin, CRP, IL-6, IL-8, MCP-1, and TNF-alpha concentrations significantly increased during the surgery. Baseline FGF-21 mRNA expression in skeletal muscle was higher than in both adipose tissue depots and it was not affected by the surgery. Epicardial fat FGF-21 mRNA increased after surgery. Muscle FGF-21 mRNA positively correlated with blood glucose levels at the end of the surgery. Our data suggest a possible role of FGF-21 in the regulation of glucose metabolism and insulin sensitivity in surgery-related stress.
Asunto(s)
Tejido Adiposo/metabolismo , Puente de Arteria Coronaria/efectos adversos , Factores de Crecimiento de Fibroblastos/metabolismo , Resistencia a la Insulina , Pericardio/metabolismo , Síndrome de Respuesta Inflamatoria Sistémica/etiología , Síndrome de Respuesta Inflamatoria Sistémica/metabolismo , Anciano , Factores de Crecimiento de Fibroblastos/genética , Humanos , Masculino , Persona de Mediana Edad , ARN Mensajero/metabolismo , Regulación hacia ArribaRESUMEN
It was demonstrated that estrogen deficiency and consuming high fat (HF) diet enhanced orexigenic activity of ghrelin. Therefore, we hypothesized that antagonizing of ghrelin action would attenuate food intake and body weight in mice obese both from ovariectomy (OVX) and feeding a HF diet. Ghrelin receptor antagonist [D-Lys(3)]GHRP-6 after seven days of subcutaneous treatment markedly decreased food intake in OVX mice fed both HF and standard diets; furthermore, it reduced body weight and blood glucose, insulin and leptin, and increased ß-hydroxybutyrate level and uncoupling-protein-1 mRNA in brown adipose tissue. Pair-feeding revealed that effect of [D-Lys(3)]GHRP-6 was primary anorexigenic. Estrogen supplementation reduced anorexigenic effects of [D-Lys(3)]GHRP-6. OVX [D-Lys(3)]GHRP-6 treatment in mice on HF diet resulted in markedly increased circulating level and liver expression of a major metabolic regulator, fibroblast growth factor 21. Our data suggest that ghrelin antagonists could be especially beneficial in individuals with common obesity combined with estrogen deficiency.
Asunto(s)
Adiposidad/efectos de los fármacos , Dieta Alta en Grasa , Modelos Animales , Obesidad/fisiopatología , Oligopéptidos/farmacología , Posmenopausia/metabolismo , Receptores de Ghrelina/antagonistas & inhibidores , Tejido Adiposo Pardo/metabolismo , Animales , Conducta Animal/efectos de los fármacos , Peso Corporal/efectos de los fármacos , Ingestión de Alimentos/efectos de los fármacos , Estrógenos/administración & dosificación , Estrógenos/deficiencia , Femenino , Ghrelina/metabolismo , Transportador de Glucosa de Tipo 1/genética , Transportador de Glucosa de Tipo 1/metabolismo , Humanos , Canales Iónicos/genética , Canales Iónicos/metabolismo , Masculino , Ratones , Ratones Endogámicos C57BL , Proteínas Mitocondriales/genética , Proteínas Mitocondriales/metabolismo , Actividad Motora/efectos de los fármacos , Ovariectomía , PPAR alfa/genética , PPAR alfa/metabolismo , Receptores de Ghrelina/genética , Receptores de Ghrelina/metabolismo , Proteína Desacopladora 1RESUMEN
The aim of our study was to measure serum concentrations of fibroblast growth factor 19 (FGF-19) in patients with obesity (OB), obesity and type 2 diabetes mellitus (T2DM) and healthy subjects (C) at baseline and after selected interventions. We measured serum FGF-19 levels and other biochemical and hormonal parameters in 29 OB and 19 T2DM females and 30 sex- and age-matched control subjects. The interventions were acute hyperinsulinemia during isoglycemic-hyperinsulinemic clamp (n=11 for T2DM and 10 for C), very-low calorie diet (VLCD, n=12 for OB) and 3 months treatment with PPAR-alpha agonist fenofibrate (n=11 for T2DM). Baseline serum FGF-19 levels were significantly lower in OB relative to C group (132.1+/-12.7 vs. 202.2+/-16.7 pg/ml, p<0.05), while no significant difference was observed between T2DM and OB or control group. Acute hyperinsulinemia tended to decrease FGF-19 levels in both healthy and T2DM subjects. Three weeks of VLCD in OB group had no significant effect on FGF-19, whereas three months of fenofibrate treatment markedly reduced FGF-19 levels in T2DM patients (194.58+/-26.2 vs. 107.47+/-25.0 pg/ml, p<0.05). We conclude that FGF-19 levels in our study were at least partially dependent upon nutritional status, but were not related to parameters of glucose metabolism or insulin sensitivity.
Asunto(s)
Restricción Calórica , Diabetes Mellitus Tipo 2/sangre , Factores de Crecimiento de Fibroblastos/sangre , Hiperinsulinismo/sangre , Obesidad/sangre , PPAR alfa/agonistas , PPAR alfa/fisiología , Enfermedad Aguda , Adulto , Biomarcadores/sangre , Glucemia/metabolismo , Restricción Calórica/métodos , Diabetes Mellitus Tipo 2/terapia , Femenino , Fenofibrato/farmacología , Fenofibrato/uso terapéutico , Humanos , Hiperinsulinismo/terapia , Resistencia a la Insulina , Persona de Mediana Edad , Resultado del TratamientoRESUMEN
CONTEXT: Low-grade inflammation links obesity, type 2 diabetes mellitus (T2DM), and cardiovascular diseases. OBJECTIVE: To explore the expression profile of genes involved in inflammatory pathways in adipose tissue and peripheral monocytes (PM) of obese patients with and without T2DM at baseline and after dietary intervention. DESIGN: Two-week intervention study with very-low-calorie diet (VLCD). SETTING: University hospital. PATIENTS: Twelve obese females with T2DM, 8 obese nondiabetic females (OB) and 15 healthy age-matched females. INTERVENTION: Two weeks of VLCD (2500 kJ/d). MAIN OUTCOME MEASURES: Metabolic parameters, circulating cytokines, hormones, and mRNA expression of 39 genes in sc adipose tissue (SCAT) and PM. RESULTS: Both T2DM and OB group had significantly increased serum concentrations of circulating proinflammatory factors (C-reactive protein, TNFα, IL-6, IL-8), mRNA expression of macrophage antigen CD68 and proinflammatory chemokines (CCL-2, -3, -7, -8, -17, -22) in SCAT and complementary chemokine receptors (CCR-1, -2, -3, -5) and other proinflammatory receptors (toll-like receptor 2 and 4, TNF receptor superfamily 1A and 1B, IL-6R) in PM, with OB group showing less pronounced chemoattracting and proinflammatory profile compared to T2DM group. In T2DM patients VLCD decreased body weight, improved metabolic profile, and decreased mRNA expression of up-regulated CCRs in PM and chemokines [CCL 8, chemokine (C-X-C motif) ligand 10] in SCAT. VLCD markedly increased mRNA expression of T-lymphocyte attracting chemokine CCL-17 in SCAT. CONCLUSION: Obese patients with and without T2DM have increased mRNA expression of chemotactic and proinflammatory factors in SCAT and expression of corresponding receptors in PM. Two weeks of VLCD significantly improved this profile in T2DM patients.